FDA 483 - CSPC Ouyi Pharmaceutical Co., Ltd. - May 17, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of CSPC Ouyi Pharmaceutical Co., Ltd. in Shijiazhuang, China, revealed that the firm's examination and testing procedures for drug products and in-process materials were inadequate. Specifically, the visual inspection process for tablets did not properly account for unique defects, and the standard operating procedure for tablet press post-processing lacked sufficient detail for defect detection. These issues indicate a moderate severity concern regarding quality control and product efficacy.
ID · 5cf2568f-ab81-46f8-84b1-3550d3ddb29a